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The discovery of the tissue-protective activities of erythropoietin (EPO) has underlined the
importance of some cytokines in tissue-protection, repair, and remodeling. As such activi-
ties have been reported for other cytokines, we asked whether we could define a class of
tissue-protective cytokines. We therefore explored a novel approach based on functional
clustering. In this pilot study, we started by analyzing a small number of cytokines (30).
We functionally classified the 30 cytokines according to their interactions by using the
bioinformatics tool STRING (Search Tool for the Retrieval of Interacting Genes), followed
by hierarchical cluster analysis.The results of this functional clustering were different from
those obtained by clustering cytokines simply according to their sequence. We previously
reported that the protective activity of EPO in a model of cerebral ischemia was paral-
leled by an upregulation of synaptic plasticity genes, particularly early growth response 2
(EGR2).To assess the predictivity of functional clustering, we tested some of the cytokines
clustering close to EPO (interleukin-11, IL-11; kit ligand, KITLG; leukemia inhibitory factor,
LIF; thrombopoietin, THPO) in an in vitro model of human neuronal cells for their ability
to induce EGR2. Two of these, LIF and IL-11, induced EGR2 expression. Although these
data would need to be extended to a larger number of cytokines and the biological valida-
tion should be done using more robust in vivo models, rather then just one cell line, this
study shows the feasibility of this approach. This type of functional cluster analysis could
be extended to other fields of cytokine research and help design biological experiments.
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INTRODUCTION
The cytokine field was initially focused on the role of cytokines as
humoral factors in host defense against infection and cancer, and
the discoveries of interferon (IFN), interleukins (IL)-1 and -2 (1).
This led to exploring their use in the therapy of viral infections and
cancer, and IFN is now used for the therapy of some viral diseases.
However, the big bang in the field took place with the discovery
of the proinflammatory activity of some cytokines, particularly
IL-1 and TNF (2, 3), as this concept led to the development of
new anti-inflammatory agents such as anti-TNF antibodies and
soluble receptors, used in millions of patients.
The current focus on stem cell therapy and regenerative med-
icine has put an emphasis on the protective functions of some
cytokines. Our earlier finding that erythropoietin (EPO) has neu-
roprotective activities in models of brain and spinal cord injury
(4) led to the subsequent discovery of protective actions of EPO
outside the CNS and to the use of the term tissue-protective
cytokine [reviewed in Ref. (5, 6)]. Although this term had since
been used for other cytokines (7), it has recently been used to
define EPO or EPO-derived molecules, such as carbamylated EPO
or EPO-derived peptides (8, 9).
It should be noted, however, that protective/regenerative func-
tions of some cytokines have long been known. For instance
transforming growth factor beta (TGFb) has been extensively
studied in the context of wound repair (10), and IL-6 for increasing
myelination (11).
We recently performed a microarray study to investigate the
effect of EPO on the gene expression profile in rat ischemic brain
and identified several genes associated with neuronal plasticity
(12). These included early growth response 2 (EGR2), which
is a transcription factor important in myelination. In fact, we
could show that EPO promotes myelination, thus suggesting some
similarity with IL-6 (13).
Another major action of some cytokines that can be regarded
as protective/reparative is the stem cells-mobilizing action of EPO,
Kit ligand/stem cell factor (KITLG), G-CSF, and GM-CSF (14, 15).
Despite studies in the literature reporting protective or repar-
ative actions of various cytokines, no attempt has been made to
define a functional family of tissue protective cytokines [see Ref.
(16) for a review].
In the present study, we identify a cluster of tissue-protective
cytokines using a bioinformatics approach. In particular, we have
used the STRING (Search Tool for the Retrieval of Interact-
ing Genes/Proteins) database (17). The STRING database inte-
grates data from multiple experimental repositories that describe
protein–protein physical and functional associations. These data
are then augmented by predicted functional associations, from a
number of complementary algorithms that utilize evolutionary
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information. STRING also identifies putative protein–protein
associations using a text-mining algorithm. We used STRING to
identify a comprehensive set of interactors for EPO and 29 other
cytokines that belong to different structural families. We then
identified the subset of these interactors that were related to tissue-
protection or regeneration functions using the gene ontology
(GO) classification performed by DAVID (Database for annota-
tion, visualization, and integrated discovery) (18). The cytokines
were grouped into functional subclasses based on their tissue-
protective interactors using standard hierarchical cluster analysis.
We predicted that those cytokines that cluster close to EPO would
be similar in terms of tissue-protective functions.
To assess the effectiveness of this strategy, four cytokines were
chosen and their ability to protect tissue from ischemic damage
was assessed experimentally by determining the degree to which
they induce EGR2 expression in neuronal cells, an experimental
model in which EPO shows activity (12).
We find that this strategy is far more effective at identify-
ing cytokines with common biological functions than clustering
simply based on amino acid sequence similarity.
MATERIALS AND METHODS
IDENTIFICATION OF CYTOKINE INTERACTORS USING STRING
A list of functional interactors for each cytokine was obtained using
the STRING database, available online1 (17). Thirty cytokines,
including EPO (Table 1) were input into STRING to obtain a
list of functional interactors. STRING assigns to each reported
functional association a confidence score, which is dependent on
both the experimental method on which the functional associa-
tion prediction is based, and on the reliability of computational
approaches used for prediction, so that each functional association
can be confidence weighted as a measure of reliability.
For each cytokine, search criteria were: a maximum of 500
interactors, combined confidence score >0.2 and use of all active
prediction methods, including text mining. No“white nodes”were
requested in the search criteria. This refers to secondary interac-
tors, proteins that are predicted functional partners of primary
interactors with the search cytokine, but which do not interact
directly with the search cytokine.
Data for each cytokine was saved as a text file and imported
to Microsoft Excel for processing. Primary interactors with each
cytokine and the combined confidence score for each respective
interaction were extracted from all 30 datasets and pooled onto a
single spreadsheet. The lowest scoring interactions that straddled
the 500 interactors search limit were deleted as it would not be
clear how many other predicted functional interactors with this
score existed without increasing the upper search limit past 500. A
Perl program was used to integrate all the interaction data into a
single data matrix for further analysis.
FUNCTIONAL ANNOTATION
The interactors were functionally annotated using the DAVID
database, accessible online2 (18).
1http://string-db.org/
2http://david.abcc.ncifcrf.gov/
Table 1 | List of cytokines studied in the cluster analysis.
Cytokine Abbreviation
Brain-derived neurotrophic factor BDNF
Cardiotrophin-like cytokine factor 1 CLCF1
Ciliary neurotrophic factor CNTF
Cardiotrophin 1 CTF1
Erythropoietin EPO
Granulocyte colony stimulating factor G-CSF
Growth hormone GH
Granulocyte-macrophage colony stimulating factor (CSF2) GM-CSF
Interferon alpha 1 IFNA-1
Interleukin-10 IL-10
Interleukin-11 IL-11
Interleukin-12A IL-12A
Interleukin-18 IL-18
Interleukin-1 alpha IL-1A
Interleukin-1 beta IL-1B
Interleukin-2 IL-2
Interleukin-21 IL-21
Interleukin-3 IL-3
Interleukin-4 IL-4
Interleukin-5 IL-5
Interleukin-6 IL-6
Interleukin-1 receptor antagonist IL-1RN
Kit ligand/stem cell factor KITLG
Leptin LEP
Leukemia inhibitory factor LIF
Nerve growth factor NGF
Oncostatin M OSM
Prolactin PRL
Thrombopoietin THPO
Tumor necrosis factor alpha TNF
CLUSTER ANALYSES
Clustalw3 was used to cluster the proteins by sequence similarity,
whereas the functional interactors patterns were analyzed using
the Genesis software4 (Version 1.7.6 for Mac OSX).
CELL CULTURE
The rat neuroblastoma B104 cell line, genetically modified to
express EPOR constitutively, as reported (12), was cultured
in DMEM high-glucose (PAA Laboratories, Yevil, UK) sup-
plemented with 10% (vol/vol) FBS, 100 U/ml penicillin and
100µg/ml streptomycin (Invitrogen/Life Technologies, Carlsbad,
CA, USA; complete medium). Before cytokine treatment, cells
were switched to medium without serum with 5µg/ml insulin,
5µg/ml transferrin, and 5 ng/ml selenium (Sigma-Aldrich, St.
Louis, MO, USA) and incubated for 4 h. Cells were treated with
80 ng/ml recombinant human EPO (rhEPO; Creative Dynam-
ics, New York, NY, USA), 20 ng/ml recombinant mouse leukemia
inhibitory factor (rmLIF; Sigma-Aldrich), 50 ng/ml recombi-
nant human interleukin-11 (rhIL-11), 50 ng/ml recombinant rat
3http://www.ebi.ac.uk/Tools/msa/clustalw2/
4https://genome.tugraz.at/genesisclient/genesisclient_description.shtml
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KITLG (rrKITLG), or 50 ng/ml recombinant human thrombopoi-
etin (rhTHPO) (all from R&D Systems, Minneapolis, MN, USA).
After 1 h, total RNA was extracted and Egr2 mRNA quantified
by qPCR.
qPCR
Total RNA was extracted from cultured cells using TRIzol (Invit-
rogen/Life Technologies). RNA quality and concentration were
determined using a NanoDrop ND-1000 (NanoDrop Technolo-
gies/Thermo Fisher Scientific, Wilmington, DE, USA). Reverse
transcription and real time qPCR were carried out as reported (12),
using TaqMan gene expression assays for rat Egr2 and rat glyc-
eraldehyde 3-phosphate dehydrogenase (GAPDH, housekeeping
gene), commercially available from Applied Biosystems/Life Tech-
nologies). For quantification, we used the comparative threshold
cycle (∆∆Ct) method, following Applied Biosystems/Life Tech-
nologies guidelines. Results were normalized to GAPDH and
expressed as arbitrary units, using as a calibrator one of the control
samples. Statistical significance was determined using the unpaired
two-tailed Student t -test.
RESULTS
The main steps involved in data processing are summarized in
Figure 1. The primary interactors for 30 cytokines including EPO
(Table 1) were identified using the STRING database and the com-
bined confidence score for each respective interaction extracted.
In total, 4250 proteins were identified as having a functional
association with at least one of the proteins in the data set.
To compare the patterns of interaction of the cytokines, a
matrix was constructed that combined all the interactions iden-
tified. The matrix was populated by the interaction confidence
for each cytokine, scored against all 4250 identified interactors.
Where a functional interaction had been identified by STRING,
the interaction was defined by the combined confidence score. If
no interaction was identified, a score of −1 was recorded.
EXTRACTION OF INTERACTORS INVOLVED IN TISSUE-PROTECTION
USING DAVID
All the interactors were annotated using the DAVID functional
annotation resource (see text footnote 2) and GO terms were
assigned to each. Interactors with no associated GO terms were
excluded, thus obtaining a dataset of 4338 interactors out of 4520.
Since our aim was to identify cytokines functionally similar in
terms of protective/reparative functions, therefore sharing inter-
actors involved in “repair or protection,” we chose to select only
the interactors identified by GO terms containing the text listed in
Table 2.
The respective interactors were then extracted from the com-
plete list. Therefore, only 1035 interactors involved in repair or
protection were used for the subsequent cluster analysis (Table S1
in Supplementary Material).
CLUSTER ANALYSIS
The final dataset, consisting of the 30 cytokines scored against
the 1035 genes extracted with DAVID (Table S1 in Supplementary
Material), was imported into the GENESIS analysis suite (Gene-
sis version 1.7.6 for Mac OSX). Hierarchical clustering was then
FIGURE 1 | Flow chart summarizing the steps involved in data
processing.
Table 2 | List of GO terms text strings used.
Plasticity
Wound healing
Remodeling
Regeneration
Apoptosis
Angiogenesis
Neurogenesis
Neuron differentiation
Myelination
performed and the results are shown in Figure 2, left panel. For
purpose of comparison, Figure 2, right panel, shows the results of
clustering proteins according to their sequence using ClustalW2
(see text footnote 3), visualized as distance trees with JalView5.
It can be seen that the distribution of cytokines within primary,
secondary, and tertiary clusters to EPO are markedly different in
the “functional” cluster and in the sequence alignment cluster.
USING FUNCTIONAL CLUSTER ANALYSIS TO PREDICT BIOLOGICAL
ACTIVITY
Cytokines selected from primary, secondary, and tertiary clusters
with respect to EPO (IL-11, KITLG, LIF, THPO) were chosen as
5http://www.jalview.org/
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FIGURE 2 | Functional (left) and sequence (right) clustering of 30
cytokines. Cytokines were functionally clustered, using Genesis, according
to shared interactors involved in “repair/protection”, identified by GO terms
containing the text listed inTable 2 (left) or according to their sequence,
using ClustalW2 (right).
experimental candidates, to test their effect on Egr2 mRNA expres-
sion in serum-starved EPOR-B104 neuroblastoma cells exactly as
we described previously (12).
As shown Figure 3, EPO, IL-11, and LIF significantly increased
the expression of Egr2 mRNA after serum deprivation when com-
pared to a control sample. Neither KITLG nor THPO at 50 ng/ml
elicited a significant elevation in Egr2 mRNA expression, at least
in the experimental conditions used.
IDENTIFICATION OF GENES INVOLVED IN TISSUE-PROTECTION
As the experimental results confirmed that EPO, LIF, and IL-11
exhibit similar tissue protective functions, we decided to explore
the similarities on their protein interaction networks. We iden-
tified the genes predicted to have a functional association with
EPO, LIF, and IL-11. Venn diagrams were used to display the
similarities among EPO, LIF, and IL-11 in terms of shared interac-
tors (Figure 4). Thirty-two genes were predicted to have functional
associations with all three cytokines (Table 3).
IDENTIFICATION OF OTHER FUNCTIONAL FAMILIES
To further explore the potential of this strategy, we also per-
formed an analysis where cytokines were functionally clustered in
terms of inflammatory functions. To this aim, we selected only
FIGURE 3 | Effect of EPO, LIF, IL-11, KITLG, andTHPO on Egr2 mRNA in
neuronal cells. Cells were plated in 24-well plates at 120,000 cells/ml in
complete medium. After overnight incubation, the cells were deprived of
serum for 4 h and then stimulated with EPO (80 ng/ml), LIF (20 ng/ml), IL-11
(50 ng/ml), KITLG (50 ng/ml), or THPO (50 ng/ml) for 1 h. Egr2 mRNA was
measured by qPCR, using GAPDH as a housekeeping gene. Results
represent the change in expression level vs. one of the control (ctr)
samples, and are the mean±SD of triplicate samples assayed in duplicate.
One representative experiment out of three is shown. ***P <0.001 by
Student’s t -test.
FIGURE 4 | Venn diagram of EPO, LIF, and IL-11 interactors. A Venn
diagram was constructed to identify commonalities in the interaction
partners of EPO, LIF, and IL-11. Total number of interactors for each cytokine:
EPO, 162; IL-11, 111; LIF, 174. The 32 interactors common to EPO, IL-11, and
LIF are listed inTable 3.
the interactors having “inflammatory” in their GO terms, and
obtained 299 interactors (Table S2 in Supplementary Material). We
then clustered the cytokines based on these interactors (Figure 6),
and obtained functional families that were clearly different from
those obtained when clustering according to “tissue-protective”
interactors (Figure 2, left panel). In particular, when cytokines
were clustered according to their “inflammation-related” inter-
actors (Figure 6), EPO was closest to GH1, PRL, and THPO,
whereas in terms of tissue-protective functions EPO was closest to
G-CSF, GM-CSF, and IL-3 (Figure 2, left panel), known to share
tissue-protective activities with EPO using in certain models the
same signaling pathway through the common beta chain recep-
tor (6). Therefore, this strategy gives different results based on
the different interactors that are selected and used for the cluster
analysis.
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Table 3 | List of interactors common to EPO, LIF, and IL-11.
Gene symbol Gene name
BCL2 B-cell CLL/lymphoma 2
CSF2 Colony stimulating factor 2 (GM-CSF)
EFNB1 Ephrin B1
EP300 E1A binding protein p300
FOSL1 FOS-like antigen 1
IGF1 Insulin-like growth factor 1
IL10 Interleukin 10
IL12B Interleukin 12B
IL1A Interleukin 1 alpha
IL1B Interleukin 1 beta
IL2 Interleukin 2
IL3 Interleukin 3
IL6 Interleukin 6
IL6R Interleukin 6 receptor
IL7 Interleukin 7
INS Insulin
JAK2 Janus kinase 2
JUN Jun oncogene
LIFR Leukemia inhibitory factor receptor alpha
OSM Oncostatin M
PTH Parathyroid hormone
PTPN6 Protein tyrosine phosphatase, non-receptor type 6
PTPRC Protein tyrosine phosphatase, receptor type, C
SMAD1 SMAD family member 1
SOCS3 Suppressor of cytokine signaling 3
SOD1 Superoxide dismutase 1
SOD2 Superoxide dismutase 2
STAT1 Signal transducer and activator of transcription 1
STAT3 Signal transducer and activator of transcription 3
STAT5A Signal transducer and activator of transcription 5A
TGFB1 Transforming growth factor beta 1
TNF Tumor necrosis factor
The list of the 32 interactors common to EPO, LIF, and IL-11 was input to STRING
(confidence score >0.2, no text mining) and visualized as a network. Only five
nodes (EFNB1, IGF1, INS, PTH, and TNF) were isolated and were therefore
excluded. The remaining 27 common interactors were input to Cytoscape to
construct a biological association network (Figure 5).
DISCUSSION
This study shows a pragmatic approach to identify a functional
class of cytokines. In particular, we have tested the possibility
of defining a functional family of neuro- and tissue-protective
cytokines. We have also validated the results of the prediction by
testing some of the cytokines in vitro.
While, ideally, the way to validate the predictions would have
been to test all 30 cytokines in multiple in vivo models (e.g.,
myocardial infarction, cerebral ischemia, wound healing) this
was neither feasible nor within the scopes of this study and we
decided to use an in vitro test for this pilot study. In fact we
could demonstrate that IL-11 and LIF can induce EGR2 expres-
sion in a system where EPO is effective. Of note, the induction of
EGR2 expression by LIF or IL-11, in neurons as well as in other
FIGURE 5 | Interaction network of the 27 connected, common
interactors.
cells, was not previously known, indicating that functional clus-
tering can actually be helpful in predicting an unknown biological
activity.
However, one limitation of this study is that the in vitro exper-
iments are not necessarily confirmative because the cell line used
may not express sufficient levels of the receptor for the specific
cytokine, and this could be the reason for the lack of activ-
ity of KITLG and THPO in our system. Another limitation is
that the in vitro model used in this study (a human neurob-
lastoma cell line) is obviously tailored toward the nervous sys-
tem and is not appropriate for studying other tissue-protective
activities. For instance, KITLG administration via a lentiviral vec-
tor was reported to protect against myocardial infarctions, and
the assay we used is clearly unsuitable to study a cardioprotec-
tive activity. Furthermore, in vivo testing using the appropri-
ate models depending on the functional family explored would
be desirable to validate the results obtained with the cluster
analysis.
The observed induction of EGR2 by LIF and IL-11 might
be important in the common pro-myelinating effects of these
cytokines (19, 20), as EGR2, also known as KROX-20, is a
transcription factor involved in myelination (21).
The identification of common interactors for EPO, LIF, and
IL-11 (listed in Table 3) might also shed light on the mecha-
nism of actions of tissue-protective cytokines. These common
genes include a number of other cytokines as well as signaling
molecules belonging to the JAK/STAT pathways that were easily
predictable. However, they also include JUN and FOSL1, that are
among the early genes induced by growth factors in the nervous
system (22), genes involved in apoptosis pathway, such as BCL2
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FIGURE 6 | Functional clustering of 30 cytokines for their role in
inflammation. Cytokines were functionally clustered, using Genesis,
according to shared interactors involved in inflammation, as identified by
their GO terms.
(23), and neuroprotective factors such as IGF1 (24), that is also
involved in myelination (25).
In conclusion, this study reports for the first time a strategy
to cluster cytokines by their function. The results, although per-
formed on a limited number of cytokines, support the concept
of a functional family of tissue-protective cytokines that share the
tissue-protective activities of EPO.
Finally, although this study was aimed at defining a class or
“tissue-protective cytokines,” we also tried to use the same strategy
to identify other functional families by choosing to cluster only
for interactors containing other specific GO terms, in particular
only those related to inflammation. Indeed, EPO clustered with
different cytokines depending on the interactors selected for the
cluster analysis.
We therefore propose that this approach, if performed on a
large number of cytokines, will be helpful in identifying other
functional families.
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